II is a potent vasoconstrictor, promotes aldosterone release, facilities sympathetic activity and has other potentially harmful effects on the cardiovascular system. Reduction in blood pressure secondary to vasodilatation following ACE inhibition is greatest when the renin-angiotensin system is stimulated (e.g. following diuretic therapy or in renal artery stenosis) but ACE inhibitors also lower blood pressure when there is normal or low activity of the renin-angiotensin system. Nevertheless, Afro-Caribbeans and elderly individuals, who tend to have low renin hypertension, respond less well to monotherapy with ACE inhibitors. Inhibition of ACE (kininase II) also leads to accumulation of kinins including bradykinin which promotes vasodilator activity and may contribute to the overall effectiveness of ACE inhibitors.
Pharmacokinetics
All ACE inhibitors bind to tissue and plasma protein. Whereas free drug is eliminated relatively rapidly by the kidney predominantly by glomerular filtration, binding to tissue sites means that the plasma concentration-time profile shows a long lasting terminal elimination phase. The prototype ACE inhibitor, captopril, is absorbed and eliminated rapidly. Enalapril, like most of the later ACE inhibitors, is an inactive pro-drug that requires hydrolysis during or after absorption to generate the active acid form, enalaprilat. Lisinopril is an analogue of enalapril and is itself active. Angioedema also attributable to kinin potentiation. Rare but potentially fatal.
Hyperkalaemia due to potassium retention mediated by reduction of aldosterone. Rare except in renal impairment.
First dose hypotension of renin-angiotensin system activated. Rare in essential hypertension.
Impairment of renal function. Caution if bilateral renal artery stenosis suspected.
Taste disturbance. Rare Skin rashes. Very rare
Practical issues
The ACE inhibitor dose-blood pressure response relationship is linear at low doses, but a "plateau" is reached quickly within the therapeutic range. Further increases in dosage do not increase the peak blood pressure reduction but prolong the duration of action. The fall in blood pressure following ACE inhibition is not associated with changes in heart rate; in particular, there is no reflex tachycardia. ACE inhibitors vary in efficacy and duration of action with some but not others being suitable for once-daily dosing. Captopril has the shortest duration of action and has to be administered twice or thrice daily to provide blood pressure lowering over 24 hours. Although many ACE inhibitors are recommended for once daily dosing, for some, such as enalapril, a more consistent response is achieved by twice daily administration. Since duration of blood pressure reduction is dosedependent, with most ACE inhibitors, smooth blood pressure lowering over 24 hours is only achieved at the maximum recommended dose. To avoid precipitous initial fall in blood pressure or decline in renal function, it is generally advised to start therapy with low dosages in the elderly, and in patients with compromised renal function or heart failure.
In general ACE inhibitors are well tolerated. Other than cough and other non-specific upper respiratory symptoms, side effects are rare. Cough is not dose-dependent and is a class effect.
Altering dose or ACE inhibitor is not helpful. Concern about first dose hypotension arose from experience in patients with heart failure, accelerated hypertension or essential hypertension treated with excessive doses of diuretics and consequent sodium/volume depletion with activation of the renin-angiotensin system. This is uncommon with current low dose diuretic regimens. In the absence of a compelling indication for another drug or contraindication to an ACE inhibitor, these drugs should be used as recommended in the NICE/BHS algorithm.
Impairment
step 1 in Caucasian people aged less than 55 years step 2 with a calcium channel blocker or thiazide/thiazide-like diuretic step 3 with a calcium channel blocker plus a thiazide or thiazide-like diuretic
